ARTICLE | Clinical News
Apidra insulin glulisine regulatory update
February 28, 2011 8:00 AM UTC
sanofi-aventis received 2 warning letters from FDA regarding the company's failure to adequately address cGMP deficiencies and postmarketing reporting violations identified during FDA inspections last...